Treatment of an elderly patient with acute myelocytic leukemia transformed from myelodysplastic syndrome with decitabine in ultra-low dosage combining with transfusion of autologous cytokineinduced killer cells: a case report and review of literature

• Published in: Jie fang jun yi xue za zhi Vol. 39; no. 4; p. 315
• Main Authors: YANG, Bo, Li-li, CAI, Hai-tao, WANG, Hong-li, ZHU, Xiao-hua, CHI, Rui-li, YU, YANG, Yang, Hai-hong, RAN, Li-jun, XIN, Shan-qian, YAO, Xue-chun, LU
• Format: Journal Article
• Language: Chinese
• Published: Beijing People's Military Medical Press 01.04.2014
• Subjects: Case reports; Leukemia; Patients
• ISSN: 0577-7402
• DOI: 10.11855/j.issn.0577-7402.2014.04.13

Objective　To investigate the efficacy and safety of decitabine in ultra-low dose combining with autologous cytokine-induced killer (CIK) cells for treatment of elderly patients with acute myelocytic leukemia (AML) transformed from myelodysplastic syndrome (MDS). Methods　An 83-year-old patient with initial diagnosis of MDS-RA was treated with amifostine combined with erythropoietin (EPO), and hemogram was improved nearly to normal lasting about three and a half years. Then the patient's morbidity transformed to chronic myelomonocytic leukemia (AML-M4) two months later. Then the patient was treated with an ultra-low dose of decitabine combining with autologous CIK cells. The detailed treatment included decitabine 10mg, d1-5, and CIK cells transfusion (2×109-8×109 each time) d14; rhIL-2 2mU d15-19. 28-day treatment was accounted as one treatment course. Side effects, changes in hemogram, signs of recuperation and duration of survival were systematically observed. Further, the literature concerning decitabine for